Fortis Healthcare Ltd is a Medical Care Facilities company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Fortis Healthcare Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Medical Care Facilities. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹3,492 Cr | ₹3,966 Cr | ₹4,199 Cr | |||||||||
| Expenses | ₹3,430 Cr | ₹3,857 Cr | ₹4,106 Cr | |||||||||
| Operating Profit | ₹62 Cr | ₹109 Cr | ₹92 Cr | |||||||||
| OPM % | 2.0% | 3.0% | 2.0% | |||||||||
| Other Income | ₹152 Cr | ₹92 Cr | ₹299 Cr | |||||||||
| Depreciation | ₹183 Cr | ₹235 Cr | ₹225 Cr | |||||||||
| Interest | ₹250 Cr | ₹152 Cr | ₹133 Cr | |||||||||
| Profit Before Tax | ₹-219 Cr | ₹-185 Cr | ₹34 Cr | |||||||||
| Tax | ₹-219 Cr | ₹-185 Cr | ₹34 Cr | |||||||||
| Net Profit | ₹-218 Cr | ₹-130 Cr | ₹42 Cr | |||||||||
| EPS (₹) | -4.7 | -3.1 | 0.4 | |||||||||
| Dividend Payout % | 0% | -1% | 0% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,560 Cr | ₹1,643 Cr | ₹1,657 Cr | ₹1,770 Cr | ||||||||
| Expenses | ₹1,283 Cr | ₹1,372 Cr | ₹1,386 Cr | ₹1,440 Cr | ||||||||
| Operating Profit | ₹276 Cr | ₹271 Cr | ₹272 Cr | ₹330 Cr | ||||||||
| OPM % | 18.0% | 16.0% | 16.0% | 19.0% | ||||||||
| Depreciation | ₹83 Cr | ₹82 Cr | ₹79 Cr | ₹84 Cr | ||||||||
| Interest | ₹33 Cr | ₹32 Cr | ₹31 Cr | ₹32 Cr | ||||||||
| Net Profit | ₹142 Cr | ₹138 Cr | ₹124 Cr | ₹184 Cr | ||||||||
| EPS (₹) | 1.7 | 1.8 | 1.5 | 2.3 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹463 Cr | ₹463 Cr | ₹463 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,820 Cr | ₹3,585 Cr | ₹3,998 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹2,550 Cr | ₹1,784 Cr | ₹1,513 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,018 Cr | ₹1,760 Cr | ₹1,257 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹7,851 Cr | ₹7,592 Cr | ₹7,232 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹4,147 Cr | ₹4,218 Cr | ₹3,642 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,817 Cr | ₹1,464 Cr | ₹1,452 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹1,739 Cr | ₹1,682 Cr | ₹1,913 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹7,851 Cr | ₹7,592 Cr | ₹7,232 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹479 Cr | ₹2,503 Cr | ₹-3,217 Cr | — |
| Mar 2016 | ₹24 Cr | ₹213 Cr | ₹-304 Cr | — |
| Mar 2017 | ₹195 Cr | ₹122 Cr | ₹-354 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.